

# Cortellis Product Intelligence


## 医薬品関連の契約情報を収集する

ディール情報コンテンツは契約締結、買収候補先やパートナー提携先の探索、競合企業の調査等に必要な情報を提供します。

注: コンテンツをご利用頂けるのはCortellis Product IntelligenceのGlobalとPremiumライセンスをご契約のユーザーのみとなります。

### 検索事例: ペムブロリズマブに関する契約情報の収集

#### 1. クイックサーチからペムブロリズマブの製品レコードを検索



#### 2. 製品レコードのディールタブをクリックすると、ディールごとに関連する企業やディールの効力を発揮する国/地域、ディールのステータスやバリュー（情報が付与されたディールに限る）といった情報を明確に確認できます。

The screenshot shows the 'Deals' page for 'pembrolizumab'. The page has a navigation bar with various tabs like 'PRODUCT KEY INSIGHTS', 'API MANUFACTURERS', etc., and a 'DEALS' tab is selected. Below the navigation bar, there are filters for 'Partner Country/Territory' and 'Agreement Type'. A callout box points to the 'Customize Columns' and 'Export' buttons, with the text: '表示する項目列のカスタマイズやデータ出力が可能です。' (Customization of the items to be displayed and data output is possible.)

DEAL TITLE	PRINCIPAL COMPANY	PRINCIPAL COUNTRY/TERRITORY	PRINCIPAL CORPORATE GROUP	PARTNER COMPANY	PARTNER COUNTRY/TERRITORY	PARTNER CORPORATE GROUP	AGREE
BioInvent to evaluate BI-1607 in combination with ipilimumab and MSD's Keytruda against metastatic melanoma	BioInvent International AB	Sweden	BioInvent International AB	MSD International Business G...	Switzerland	Merck and Co Inc	Drug -
CytomX to evaluate CX-801 in combination with Merck's pembrolizumab against cancer	CytomX Therapeutics Inc	US	CytomX Therapeutics LLC	Merck & Co Inc	US	Merck and Co Inc	Drug -
University of California to							

### 3. デールタイトルをクリックするとデール情報の詳細を確認できます。

Deals	
Filters Partner Country/Territory <span>▼</span> A	
Customize Columns <span>⌵</span> Export <span>⌵</span>	
DEAL TITLE <span>⌵</span>	PRINCIPAL CO
BiInvent to evaluate BI-1607 in combination with ipilimumab and MSD's Keytruda against metastatic melanoma	<a href="#">BiInvent Inter</a>
CytomX to evaluate CX-801 in combination with Merck's pembrolizumab against cancer	<a href="#">CytomX Therap</a>
University of California to conduct phase II study of ALX Oncology's evorpacept in combination with pembrolizumab against oropharyngeal cancer	<a href="#">University of C</a>
University of Chicago Medicine to conduct a phase II/III for HOOKIPA Pharma's HB-200 in combination with	<a href="#">The University</a>

## Deal Details

### Details and Information

#### Deal Title

BiInvent to evaluate BI-1607 in combination with ipilimumab and MSD's Keytruda against metastatic melanoma

#### More Information

[Cortellis Competitive Intelligence](#)

#### Status

Active

#### Principal Company

[BiInvent International AB](#)

#### Principal Country/Territory

Sweden

#### Partner Company

[MSD International Business GmbH](#)

#### Partner Country/Territory

Switzerland

#### Deal Start Date

17-Jul-2024

#### Deal End Date

No data

#### Agreement Type

Drug - Early Research/Development

#### Value (\$M)

No data

#### Involved Products

[ipilimumab](#)

[pembrolizumab](#)

### Events

**17-Jul-2024** - In July 2024, BiInvent International signed a clinical trial collaboration and supply agreement to evaluate BI-1607 in combination with Ipilimumab and MSD International Business' Keytruda (pembrolizumab) against metastatic melanoma. - BI-1607 is a phase II human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) targeting Fc gamma receptor IIB for advanced solid tumors including breast, gastric, gastroesophageal junction adenocarcinoma and esophageal cancer. - Keytruda is a launched humanized IgG4 monoclonal antibody against programmed cell death protein-1 (PD-1) for different types of cancer. - Ipilimumab is a launched immunostimulatory human mAb against cytotoxic T-lymphocyte antigen-4 (CTLA-4) for cancers. - MSD would provide Keytruda for phase II open-label study. - Financial terms were not disclosed.

### Sources

BiInvent International AB, "BiInvent Announces New Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BI-1607 in Combination with KEYTRUDA (Pembrolizumab) and Ipilimumab", Press Release, issue: July 17, 2024